Clinical Determinants of Durable Clinical Benefit to Pembrolizumab in Veterans with Advanced Non-Small Cell Lung Cancer

We evaluated 24 Veterans with advanced non-small cell lung cancer treated with pembrolizumab. 41% of patients had durable clinical benefit to therapy. We showed that Veterans with high comorbidity scores responded as well as the general population to immunotherapy. A rise in absolute lymphocyte count may be associated with clinical benefit and warrants further investigation.

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2kULxaN
via IFTTT